Polyphor receives CHF40M private financing

April 18, 2017

Share:

Drug Discovery | Allschwil, Switzerland | Late Stage

Existing investors contributed 98% of the financing for Polyphor, a specialty pharma company that will use the CHF40 million funding (about €37 million) to continue developing its Murepavadin antibiotic and to conduct other research.